|
Published by: Decision Resources
Published: Jul. 27, 2009 - 43 Pages
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Importance of the Underlying Biology
- Industry Size and Major Players
- Analysis of 200 Deals
- Deal Volume
- Largest Deals
- Big Biotech, Mid-Size Pharma, and Big Pharma Deal Volumes
- Deals By Disease Category
- Types of Deals
- Big Biotech Looking for Money and Products
- Nonbiologic Product Deals
- Nucleic Acid Technology Deals
- Business Strategies
- King of Targeted Dealmaking
- Company Acquisitions: Maybe Not
- Divesting: Better Focus and Commercialization
- Passion for Biologics
- Drug Recycling
- Budesonide Story
- Drug Combinations
- Industry-Shaping Events, 2008-2009
- Impact of Big Pharma Consolidation
- Safety Concerns
- Biotech Is Hurting
- Industry Drivers
- Ten Drivers of the Autoimmune and Infl ammatory Disease Therapy Area
- Factors Holding Back the Autoimmune and Infl ammatory Disease Industry
- Industry Outlook
- Tables
- 1. Decision Resources Analysts’ Input on the Current Status and Future Directions of Autoimmune
- and Infl ammatory Disease Therapies
- 2. Autoimmune and Infl ammatory Diseases: Nonbiologic Product Deals, 2007-2009
- 3. Autoimmune and Infl ammatory Diseases: Nucleic Acid Therapeutics Deals, 2007-2009
- 4. Autoimmune and Infl ammatory Diseases: Antibody Deals, 2007-2009
- 5. Autoimmune and Infl ammatory Diseases: Peptide and Recombinant Protein Deals, 2007-2009
- 6. Autoimmune and Infl ammatory Diseases: Drug Delivery and Formulation Technology Deals,
- 2007-2009
- Figures
- 1. Autoimmune and Infl ammatory Diseases: Top 25 Companies by Worldwide Sales, 2008 and 2014
- 2. Autoimmune and Infl ammatory Diseases: Deal Volume Based on Potential Deal Size, 2007-2009
- 3. Autoimmune and Infl ammatory Diseases: the Largest Deals, 2007-2009
- 4. Autoimmune and Infl ammatory Diseases: Big Pharma, Mid-Size Pharma, and Big Biotech Deal
- Volume, 2007-2009
- 5. Deals in the Autoimmune and Infl ammatory Therapy Area by Categories of Disease, 2007-2009
- 6. Types of Autoimmune and Infl ammatory Disease Deals, 2007-2009
- 7. NF-ęB Pathway
- 8. Development Timeline for the Tumor Necrosis Factor-Alpha Blocker Humira (adalimumab)
AbstractIntroduction
Better diagnostics, the means to treat earlier stage-disease, disease-modifying therapies, and disease prevention
are the holy grails of autoimmune and infl ammatory disease drug development. However, basic science and
redundant biological pathways are holding back this therapy area. In this report, we investigate the autoimmune
and infl ammatory disease industry. We analyze 200 deals in this therapy area for 2007, 2008, and the fi rst fi ve
months of 2009. We assess what types of deals companies are executing and what business strategies they are
deploying for future success. We discuss recent industry-shaping events, industry drivers, and barriers that are
holding back this therapy area.
Questions Answered in This Report
- Analyzing deals opens up a window to a company’s business strategies. What do the 200 deals related to autoimmune and infl ammatory diseases that took place in 2007, 2008, and the fi rst fi ve months of 2009 indicate about the business strategies of Big Biotech, Mid-Size Pharma, and Big Pharma? What technologies
are hot? What new targets were licensed or optioned?
- Three mega-mergers were announced in early 2009. What impact will these deals have on this therapy area? Why did Pfi zer CEO Jeffrey Kindler think that Wyeth was the right answer for Pfi zer? What trouble might Merck & Co. have with the Schering-Plough acquisition? What might prevent Roche from achieving its goals in its acquisition of Genentech?
- The number of generics and branded generics is rising in some segments of this therapy area. Which diseases are seeing an increase in these types of agents and why? What do GlaxoSmithKline’s recent deals with Aspen Pharmacare and Dr Reddy’s Laboratories indicate about this company’s current strategies?
Scope
- Therapy area: Diseases; market size, top 25 companies by worldwide sales, major brands.
- 200 deals: Total deal volume; biobucks; 20 largest deals; Big Biotech, Mid-Size Pharma and Big
Pharma deals; most active disease areas; most active companies; top fi ve deals by technology, outlicensing,
divesting, new targets, biological pathways; nucleic acid therapeutics; budesonide deals;
reformulations; inhaler issues; combination products.
- Business strategies: Inlicensing, outlicensing, divesting low priority R&D programs, targeted acquisitions,
benefi ts of a portfolio of modest products, milestone-driven dealmaking, shared development
risk, emerging markets, generics markets, branded generics, life-cycle management, optimizing the
commercialization of off-patent drugs, a passion for biologics, drug recycling and reformulations,
fi xed-dose combinations.
- Industry-shaping events: Big Pharma consolidation, market entry, safety issues, change of ownership
issues, reverse mergers, tumor necrosis factor-alpha (TNF-á) blockers, biotech’s fi nancial crisis.
- Industry outlook: Ten therapy area drivers; factors holding back this therapy area; annual growth
rates for specifi c disease areas; three events that will invigorate the therapy area; two key harbingers
of trouble to come.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.
© MarketResearch.com 2009
|
